OakChart

Lakefront Biotherapeutics NV ADR

LKFTHealthcare·Biotechnology·Belgium·Mid·NASD·Nov 11 • 3:59 PM ET

33.34-0.07 (-0.21%)
2026-11-12 02:31 CET
Market cap
2,193.54 USD m
Revenue, TTM
1,153.32 USD m
Net income, TTM
693.58 USD m
Free cash flow, TTM
-189.89 USD m
EPS diluted, TTM
10.52
P/E
3.17
Compare

Price

LKFT against its 20, 50 and 200-day averages
2050200beatearnings
26.0028.0030.0032.0034.00445K890KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LKFTclose 33.3420-day 31.9950-day 30.16200-day 29.8933.3452w low

8.0% under the 52-week high of 36.24 on 24 Feb 2026. 52-week low 25.68 on 6 Aug 2026. Last 15 sessions, 12.9% high to low

Volume 0.67× normal · the line is the 50-bar volume average

Profile

LKFT
52-week range, 73% of the way up
25.6836.24

Lakefront Biotherapeutics is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Employees452
IPOJul 07, 2008
Beta0.20
ATR, 14d0.82
Rel volume0.67
Short float2.65%
Insider own25.35%
Inst own24.17%

Snapshot

6 groups

Valuation

Index-
Market Cap2.19B
Enterprise Value-364.11M
Income693.58M
Sales1.15B
Book/sh56.83
Cash/sh39.00
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees452
IPOJul 07, 2008

Ratios

P/E3.17
Forward P/E-
PEG-
P/S1.90
P/B0.59
P/C0.85
P/FCF-
EV/EBITDA-
EV/Sales-0.32
Quick Ratio32.70
Current Ratio32.82
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)10.52
EPS next Y-2.41
EPS next Q-0.83
EPS this Y-144.16%
EPS next Y4.92%
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y70.43% 18.16%
EPS Y/Y TTM323.94%
Sales Y/Y TTM285.48%
EPS Q/Q101.92%
Sales Q/Q-80.97%
EarningsNov 11 AMC
EPS/Sales Surpr.114.61% 32.08%

Ownership

Insider Own25.35%
Insider Trans0.00%
Inst Own24.17%
Inst Trans0.48%
ROA16.62%
ROE20.22%
ROIC18.56%
Gross Margin97.45%
Oper. Margin59.54%
Profit Margin60.14%
SMA204.23%
SMA5010.55%
SMA20011.56%
Trades-

Technical

Shs Outstand65.66M
Shs Float49.01M
Short Float2.65%
Short Ratio4.48
Short Interest1.30M
52W High36.24 -8.00%
52W Low25.68 29.83%
Volatility2.60% 2.33%
ATR (14)0.82
RSI (14)67.45
Beta0.20
Rel Volume0.67
Avg Volume290.27K
Volume195,190

Performance

Perf Week-2.20%
Perf Month14.77%
Perf Quarter18.90%
Perf Half Y18.48%
Perf YTD1.96%
Perf Year1.49%
Perf 3Y-8.26%
Perf 5Y-37.57%
Perf 10Y-44.02%
Recom2.44
Target Price33.66
Prev Close33.41
Price33.34
Change %-0.21%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 20, 2026ResumedMMorgan StanleyEqual-Weight$26-22.0%
Sep 23, 2026UpgradeRRBC Capital MktsSector Perform → Outperform$45+35.0%
Aug 21, 2026InitiatedTTD CowenBuy
Jul 10, 2026ResumedMMorgan StanleyEqual-Weight$30-10.0%
Oct 22, 2025UpgradeLLeerink PartnersMarket Perform → Outperform$40+20.0%
Aug 05, 2025DowngradeDDeutsche BankHold → Sell
Feb 14, 2025DowngradeMMorgan StanleyEqual-Weight → Underweight$31 → $22-34.0%
Nov 20, 2024DowngradeKKeplerHold → Reduce
Sep 09, 2024InitiatedLLeerink PartnersMarket Perform$24-28.0%
Aug 02, 2024DowngradeRRaymond JamesOutperform → Mkt Perform

Peers

Mkt cap
TickerCompanyMkt cap
LEGNLegend Biotech Corp ADR3.79B
AUTLAutolus Therapeutics plc ADR328.71M
ALLOAllogene Therapeutics Inc311.85M
JANXJanux Therapeutics Inc758.06M
CRBUCaribou Biosciences Inc42.21M
SANASana Biotechnology Inc686.16M
ARGXArgen X SE ADR61.48B
ARTVArtiva Biotherapeutics Inc201.19M
CABACabaletta Bio Inc312.79M
FATEFate Therapeutics Inc195.12M

Held by

AUM
TickerCompanyAUM
IBBiShares Biotechnology ETFAUM: 11.36B
SBIOALPS Medical Breakthroughs ETFAUM: 192.65M
AVDEAvantis International Equity ETFAUM: 19.73B
APIEActivePassive International Equity ETFAUM: 1.13B
AVDSAvantis International Small Cap Equity ETFAUM: 375.15M
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M
IBBQInvesco Nasdaq Biotechnology ETFAUM: 130.27M
BIBProShares Ultra Nasdaq Biotechnology 2X SharesAUM: 107.35M

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-11--0.826--7.504
2026Q22026-08-100.035-0.2360.03614.0110.602
2026Q12026-05-060.247-0.9440.2577.639.593
2025Q42026-02-2313.872-0.12713.8151,04982.874
2025Q32025-11-05-2.816-0.478-3.58482.2376.102
2025Q22025-07-23-1.846-0.228-1.81978.4680.086
2025Q12025-04-23-2.673-0.142-2.45085.2871.905
2024Q42025-02-120.289-0.5490.41083.2176.976
2024Q32024-10-30-0.809-0.169-0.84166.6476.707
2024Q22024-08-010.115-0.0740.14788.4668.844
2024Q12024-05-020.388-0.0841.48667.2271.524
2023Q42024-02-222.584-2.1402.585369.5779.007
2023Q32023-11-020.419-1.1260.426132.6691.286
2023Q22023-08-030.120-0.8170.084168.36117.497
2023Q12023-05-040.385-0.9590.378196.91109.674
2022Q42023-02-23-3.328-0.640-3.208104.96117.695

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY2.7025.8352.911972.23978.58
2020FY-5.792-5.629-5.351643.09592.46
2021FY-2.159-3.094-2.263545.18542.35
2022FY-3.500-1.344-3.487532.66586.95
2023FY3.474-1.3463.474847.86544.42
2024FY1.169-0.3161.216326.67298.8
2025FY5.734-6.4065.7261,309321.73
2026FY--2.532--32.20
2027FY--2.408--39.43
2028FY--3.004--32.83
2029FY--3.048--37.56
2030FY--3.441--43.78

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-253017.500.9712.85
2026Q3S2026-09-223117.500.9712.85
2026Q3S2026-08-203118.955.3112.85
2026Q3S2026-08-193118.945.3112.83
2026Q3S2026-08-112116.995.318.68
2026Q3S2026-08-102016.275.317.22
2026Q3S2026-07-212006.325.427.22
2026Q3S2026-05-072016.325.427.22
2026Q3S2026-03-3121010.725.4216.02
2026Q3S2026-02-2420110.305.4215.18
2026Q3S2026-02-1820081.9176.3587.48
2026Q3S2026-01-2010076.3576.3576.35
2026Q3S2025-11-1210176.3576.3576.35
2026Q3S2025-11-1120177.9876.3579.62

Estimate history

EPS, annual-2.639-0.6622.911-5.351-2.263-3.4873.4741.2165.49510.5225
Period201720182019202020212022202320242025TTM
EPS, quarterly0.147-0.8410.41-2.45-1.819-3.58413.8150.2570.035
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual143.346340.754934.462544.968573.079253.547259.169298.1671255.2591153.32
Period201720182019202020212022202320242025TTM
Sales, quarterly83.83765.74780.5378.91174.00183.1611048.4967.58214.08
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual50.93754.46564.66765.41265.55365.83665.89765.89765.89765.655
Period201720182019202020212022202320242025MRQ
Shares, quarterly65.89765.89765.89765.89765.89765.89765.89765.89765.655
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1,153.321,255.26298.17259.17253.55573.08544.97934.46340.75
Cost of Goods Sold Incl. D&A29.4592.0890.2338.9131.4327.11---
Gross Profit1,123.871,163.17207.94220.26222.12545.97---
Selling, General and Administrative Excl. Other437.15633.13454.42358.52360.34789.47788.75566.61421.84
Research and Development277.38470.67324.59239.35261.15560.48583.62459.74380.91
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income686.71530.05-246.48-138.26-138.22-243.49-263.15355.76-87.08
Interest Expense2.231.901.812.827.9714.7411.581.841.84
Unusual Expense266.47251.06-78.43-32.7230.0110.0912.04200.77-1.42
Net Income Before Taxes671.37339.56-3.346.08-74.46-159.21-366.70155.16-41.89
Income Taxes-19.51-21.02-1.9510.390.60-10.97-12.17-11.26-7.37
Consolidated Net Income690.88360.57-1.39-4.31-75.06-148.25-354.53166.42-34.52
Net Income From Continuing Operations690.88360.57-1.39-4.31-75.06-148.25-354.53166.42-34.52
Net Income693.58362.1480.13228.87-229.10-148.25-348.19167.71-34.52
EPS (Recurring)12.558.160.383.13-3.17-2.16-5.225.35-0.68
EPS (Basic, Before Extraordinaries)10.535.501.223.47-3.49-2.26-5.352.91-0.66
EPS (Diluted)10.525.501.223.47-3.49-2.26-5.352.91-0.66
EBITDA-588.57-193.97-99.36-106.80-218.31-243.78367.86-81.09
Non-Operating Income (Expense)253.3562.47166.53114.45101.74109.11-79.932.0145.62
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-20.3116.1345.9948.8762.7064.7230.43-
Price To Earnings Ratio3.173.17--561.06--68.87-
Price To Sales Ratio1.821.726.0810.3311.506.3011.8212.7514.03
Gross Margin97.4592.6669.7484.9987.6195.27---
Operating Margin59.5442.23-82.67-53.35-54.52-42.49-48.2938.07-25.56
Net Margin60.1428.8526.8888.31-90.36-25.87-63.8917.95-10.13
Shares Outstanding65.6665.9065.9065.9065.8465.5565.4164.6754.47
Market Capitalization2,193.542,193.541,812.172,678.722,921.783,613.926,474.4612,813.904,996.66

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue14.087.581,048.5083.1674.0078.9180.5365.75
Cost of Goods Sold Incl. D&A10.635.610.5312.675.3314.4516.790.02
Gross Profit3.451.971,047.9770.4968.6764.4663.7465.73
Selling, General and Administrative Excl. Other55.8477.76176.83126.71142.76238.43147.67134.36
Research and Development29.6836.22125.1486.34107.99192.34103.67102.21
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-52.40-75.79871.13-56.23-74.09-173.97-83.93-68.64
Interest Expense0.320.160.970.780.660.820.91-
Unusual Expense0.000.0027.19239.280.000.000.000.00
Net Income Before Taxes2.3416.33911.54-258.84-118.36-164.5720.30-53.98
Income Taxes0.080.080.78-20.450.03-1.91-0.10-0.63
Consolidated Net Income2.2616.25910.76-238.39-118.39-162.6620.40-53.36
Net Income From Continuing Operations2.2616.25910.76-238.39-118.39-162.6620.40-53.36
Net Income2.4516.95910.36-236.19-119.86-161.4526.99-55.40
EPS (Recurring)0.030.2614.10-1.04-1.82-2.450.41-0.84
EPS (Basic, Before Extraordinaries)0.040.2613.81-3.58-1.82-2.450.41-0.84
EPS (Diluted)0.030.2613.81-3.58-1.82-2.450.41-0.84
Non-Operating Income (Expense)55.0692.2868.5737.44-43.6110.22105.1414.65
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Price To Earnings Ratio3.175.03---20.90--
Price To Sales Ratio1.821.631.687.216.165.366.08-
Gross Margin24.4825.9599.9584.7692.7981.6979.1599.97
Operating Margin-372.12-999.6183.08-67.61-100.12-220.47-104.22-104.40
Net Margin17.42223.6186.83-284.02-161.97-204.6033.52-84.26
Shares Outstanding65.6665.9065.9065.9065.9065.9065.9065.90
Market Capitalization2,193.541,976.912,154.842,282.681,844.461,655.341,812.171,897.18

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments3,521.063,270.874,070.084,369.395,348.456,315.316,488.981,475.571,382.37
Short Term Receivables62.4891.2272.5382.55146.25212.1689.9238.3350.18
Inventories26.4253.0181.7256.4823.390.430.290.320.34
Other Current Assets0.1211.6225.210.520.2328.910.330.160.65
Total Current Assets3,610.083,426.714,249.544,508.945,518.326,556.816,579.521,514.381,433.54
Net Property, Plant & Equipment94.73127.26139.54164.63156.38126.4974.1426.4520.04
Total Investments and Advances57.04264.1621.114.881.6212.7714.258.323.50
Long-Term Note Receivable204.84181.41156.03128.01144.64197.76104.8583.9676.85
Intangible Assets1.00243.21218.13230.7068.3582.6727.984.153.00
Deferred Tax Assets0.231.531.241.454.595.484.722.872.38
Other Assets32.8738.2527.8014.1311.7713.966.555.435.25
Total Assets4,000.794,282.544,813.405,052.745,905.666,995.936,812.011,645.561,544.56
Short Term Debt Incl. Current Port. of LT Debt2.033.605.147.698.197.836.540.000.01
Accounts Payable77.19101.25148.74142.26152.73209.61159.9777.7856.58
Income Tax Payable1.120.260.061.092.031.532.291.341.04
Other Current Liabilities99.18241.86283.69406.63481.24558.32473.04172.26148.54
Total Current Liabilities179.53346.98437.64557.68644.19777.29641.84251.38206.18
Long Term Debt6.098.545.4615.6822.3528.1821.950.000.00
Provision for Risks Charges0.002.172.535.9113.3018.359.284.304.38
Deferred Tax Liabilities-21.3926.0821.50-----
Other Liabilities14.80903.681,253.561,756.062,219.782,904.792,911.021.80118.81
Total Liabilities200.421,282.761,725.282,356.832,899.633,728.623,584.09257.49329.37
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity3,800.372,999.783,088.122,695.903,006.033,267.313,227.931,388.071,215.19
Total Shareholders Equity3,800.372,999.783,088.122,695.903,006.033,267.313,227.931,388.071,215.19
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity3,800.372,999.783,088.122,695.903,006.033,267.313,227.931,388.071,215.19
Total Liabilities & Stockholders Equity4,000.794,282.544,813.405,052.745,905.666,995.936,812.011,645.561,544.56
Book Value Per Share57.6745.5246.8640.9545.8649.9549.9225.4923.86
Tangible Book Value Per Share57.6641.8343.5537.4444.8148.6949.4825.4123.80
Full-Time Employees4527041,1231,3381,3091,304845725600
Price to Book Ratio0.590.570.951.111.201.984.143.603.89
Return on Assets8.71-0.03-0.09-1.37-2.30-5.143.94-2.16-9.71
Return on Equity10.60-0.05-0.15-2.63-4.73-10.927.21-2.65-12.95
Return on Invested Capital9.512.667.40-8.45-4.90-10.575.16-2.49-10.74
Quick Ratio19.969.729.527.988.538.4310.256.026.95
Current Ratio20.119.889.718.098.578.4410.256.026.95

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income664.48362.1480.13228.87-229.10-122.02-348.19167.71-34.52
Depreciation-63.0647.8638.9131.4325.1821.3013.935.99
Other Funds (Non Cash)228.86395.11-95.5257.8973.5810.04247.14262.4517.82
Funds from Operations853.68820.3132.48325.66-124.10-86.80-79.75444.09-10.71
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1,037.91-1,042.65-346.74-748.60-398.81-508.70-403.413,152.81-157.37
Cash from Operating Activities-184.23-222.34-314.26-422.94-522.91-595.50-483.163,596.90-168.07
Capital Expenditures-5.66-15.64-88.82-20.84-38.83-68.41-104.10-51.13-16.18
Net Assets From Acquisitions-857.680.000.00-7.57-121.150.000.000.000.00
Sale of Fixed Assets and Businesses19.5822.45-9.682.620.7833.920.060.000.00
Purchase or Sale of Investments1,105.44247.82345.10101.88-1,142.44674.21963.34-4,168.12-2.59
Purchase of Investments-2,712.46-3,910.59-3,623.02-3,665.17-2,867.72-1,845.09-5,217.53-5,358.36-5.38
Sale Or Maturity of Investments3,817.904,158.413,968.123,767.051,725.282,519.306,180.871,190.242.79
Other Uses-2.21-22.57-39.89-15.10-10.510.000.000.000.00
Other Sources1.0625.670.00-0.000.000.000.000.00
Cash from Investing Activities260.52257.73206.7161.00-1,312.15639.72859.30-4,219.25-18.77
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-3.360.000.001.917.043.9232.251,500.74339.63
Repurchase of Common Pref Stock-3.360.000.000.000.000.000.000.00-18.83
Sale of Common Pref Stock0.000.000.001.917.043.9232.251,500.74358.46
Proceedsfrom Stock Options0.000.000.000.000.000.000.001,069.60349.43
Issuance or Reduction of Debt, Net--0.000.000.000.00--5.70-0.01
Change in Long Term Debt--0.000.000.000.00--0.00
Issuance of Long Term Debt--0.000.000.00---0.00
Reduction of Long Term Debt--0.000.000.000.00---
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities-7.16-3.69-5.33-5.41-1.56-4.5825.131,495.04339.62
Exchange Rate Effect5.79-5.031.93-1.6523.4367.09-80.41-11.1511.90
Net Change in Cash74.9226.67-110.95-368.99-1,813.19106.73320.85861.53164.68
Free Cash Flow-189.89-237.80-332.35-443.16-551.70-659.57-531.643,571.85-180.33
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-------3.34-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments2,560.483,436.143,521.063,583.883,654.573,561.75
Short Term Receivables64.3662.2662.4891.26103.1190.19
Inventories9.7720.3926.4226.9639.6741.60
Other Current Assets4.537.800.1213.2623.8957.30
Total Current Assets2,639.143,526.583,610.083,715.373,821.253,750.84
Net Property, Plant & Equipment87.9088.6694.73124.10128.75122.31
Total Investments and Advances84.4455.2357.0455.0455.0954.93
Intangible Assets858.230.861.008.72254.23244.09
Deferred Tax Assets0.150.190.230.981.021.59
Other Assets4.2928.2632.872.932.972.92
Total Assets3,831.413,885.714,000.794,126.504,482.024,344.51
Short Term Debt Incl. Current Port. of LT Debt1.821.832.032.042.813.32
Accounts Payable75.85110.34122.90118.24156.33182.49
Income Tax Payable1.091.051.120.410.330.21
Other Current Liabilities1.642.4953.47310.02313.54286.07
Total Current Liabilities80.40115.71179.53430.71473.01472.09
Long Term Debt5.465.596.096.777.108.41
Provision for Risks Charges0.000.000.002.482.482.24
Deferred Tax Liabilities----20.9820.22
Other Liabilities14.2515.8814.80811.36875.01873.26
Total Liabilities100.11137.18200.421,251.321,378.581,376.23
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity3,731.313,748.533,800.372,875.183,103.452,968.28
Total Shareholders Equity3,731.313,748.533,800.372,875.183,103.452,968.28
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity3,731.313,748.533,800.372,875.183,103.452,968.28
Total Liabilities & Stockholders Equity3,831.413,885.714,000.794,126.504,482.024,344.51
Book Value Per Share56.8356.8857.6743.6347.1045.04
Tangible Book Value Per Share43.7656.8757.6643.5043.2441.34
Full-Time Employees196-452---
Price to Book Ratio0.590.520.750.740.620.55
Return on Assets16.6213.869.45-11.36-6.92-4.21
Return on Equity20.2216.9811.51-16.44-10.09-6.25
Return on Invested Capital0.070.4523.92-8.20-3.85-5.42
Quick Ratio32.7030.3019.968.567.997.86
Current Ratio32.8230.4820.118.638.087.95

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income2.4616.95883.30-238.22-120.09-161.45
Other Funds (Non Cash)22.30-118.2039.60285.1759.1373.99
Funds from Operations24.75-101.25922.897.28-21.29-87.46
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-7.959.28-971.86-67.38-60.3855.00
Cash from Operating Activities16.81-91.97-48.96-60.10-81.67-32.46
Capital Expenditures-0.03-0.14-1.89-3.59-4.69-5.53
Net Assets From Acquisitions-857.680.000.000.000.000.00
Sale of Fixed Assets and Businesses3.334.282.479.49-23.0333.60
Purchase or Sale of Investments916.3864.1877.0047.8869.3754.52
Purchase of Investments-996.05-58.67-486.70-1,171.05-1,910.01-357.84
Sale Or Maturity of Investments1,912.43122.84563.701,218.931,979.38412.36
Other Uses-0.07-1.21-0.12-0.81-20.15-1.58
Other Sources0.000.000.051.0124.710.00
Cash from Investing Activities61.9367.1177.5153.9846.2281.02
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-3.360.000.000.000.000.00
Repurchase of Common Pref Stock-3.360.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.00-0.00--
Change in Long Term Debt0.000.00-0.00--
Issuance of Long Term Debt0.000.00-0.00--
Reduction of Long Term Debt0.000.00-0.00--
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-4.60-0.60-0.48-1.48-0.69-1.06
Exchange Rate Effect6.730.82-1.54-0.22-1.92-1.37
Net Change in Cash80.86-24.6426.52-7.83-38.0646.13
Free Cash Flow16.77-92.12-50.85-63.69-86.36-37.82

Revenue breakdown

Total Pharmaceutical Preparations revenue2024: 298.24M 2025: 1.25B
Belgium2024: 298.24M 2025: 1.25B
Total Pharmaceutical Preparations revenue2024: 298.24M 2025: 1.25B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.65%1.3M49.0M283.82K
2026-10-152.89%1.4M49.0M276.98K
2026-09-306.77%3.3M49.0M250.72K
2026-09-156.96%3.4M49.0M215.64K
2026-08-316.72%3.3M49.0M208.10K
2026-08-146.07%3.0M49.0M192.39K
2026-07-315.13%2.5M49.2M172.77K
2026-07-154.72%2.3M49.2M163.46K
2026-06-304.55%2.2M49.2M171.06K
2026-06-154.44%2.2M49.2M180.40K
2026-05-293.81%1.9M49.2M165.20K
2026-05-153.26%1.6M49.2M161.87K
2026-04-152.79%1.4M49.2M144.28K
2026-03-312.23%1.1M49.2M139.45K
2026-03-131.85%0.9M49.2M113.25K
2026-02-271.61%0.8M49.2M103.19K
2026-02-131.53%0.8M49.2M104.47K
2026-01-301.54%0.8M49.2M119.72K
2026-01-151.89%0.9M49.2M143.78K
2025-12-312.01%1.0M49.2M168.33K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call15.0016.0020.600.006.1400.000.000.930-0.1810.007
call17.5013.5018.100.005.1970.000.000.916-0.1750.008
call20.0011.0015.600.004.3930.000.000.899-0.1680.009
call22.508.5013.106.553.6851.000.000.878-0.1590.011
call25.006.0010.607.003.0453.000.000.850-0.1470.012
call30.001.005.702.651.93210.000.000.690-0.2120.018
call35.000.002.500.752.7053.000.000.511-0.2590.021
call40.000.004.900.052.2811.000.000.369-0.2530.020
put15.000.004.900.004.5030.000.00-0.070-0.1740.007
put17.500.004.900.003.7790.000.00-0.084-0.1680.008
put20.000.004.900.003.1420.000.00-0.102-0.1610.009
put22.500.004.900.002.5980.000.00-0.123-0.1520.011
put25.000.001.000.402.0292.000.00-0.149-0.1310.013
put30.000.004.900.952.0191320.00-0.311-0.2080.018
put35.000.105.002.400.7349.000.00-0.550-0.1520.021
put40.004.609.000.002.2190.000.00-0.630-0.2490.020

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-04SEC
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-02SEC
2026-10-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-20SEC
2026-10-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-14SEC
2026-10-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-13SEC
2026-10-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-08SEC
2026-10-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-06SEC
2026-09-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-29SEC
2026-09-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-22SEC
2026-09-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-15SEC
2026-09-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-08SEC
2026-09-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-08SEC
2026-09-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-01SEC
2026-08-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-25SEC
2026-08-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-25SEC
2026-08-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-25SEC
2026-08-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-18SEC
2026-08-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-12SEC
2026-08-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-12SEC
2026-08-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-04SEC
2026-07-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-28SEC
2026-07-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-21SEC
2026-07-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-14SEC
2026-07-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-13SEC
2026-07-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-07SEC
2026-06-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-06-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-29SEC
2026-06-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-23SEC
2026-06-23SCHEDULE 13GSEC
2026-06-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-16SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
GILEAD SCIENCES, INC.25.45%
TANG CAPITAL MANAGEMENT LLC5.75%
Madison Avenue Partners, LP5.23%
Prosight Management, LP3.10%
EcoR1 Capital, LLC2.53%
AMERIPRISE FINANCIAL INC1.93%
UBS Group AG0.99%
DME Capital Management, LP0.73%
RENAISSANCE TECHNOLOGIES LLC0.62%
BlackRock, Inc.0.51%

Funds

Fund% owned
Columbia Overseas Value Fund0.91%
iShares Biotechnology ETF0.44%
Columbia Variable Portfolio - Overseas Core Fund0.43%
Columbia Overseas Core Fund0.14%
ALPS Medical Breakthroughs ETF0.12%
Avantis International Equity ETF0.05%
Schwab International Opportunities Fund0.03%
International Value Fund0.03%
ActivePassive International Equity ETF0.03%
Steward Values Enhanced International Fund0.03%

OakChart. LKFT. Cached 15 minutes.

Some panels did not load: insider.